Novo Nordisk Shares Drop After Key Trial Failure
Shares of Novo Nordisk (NVO) fell nearly 9.5% after the company announced that its experimental heart drug, ziltivekimab, failed to reduce major adverse cardiovascular events in a key Phase 3 trial called Zeus. The drug successfully reduced inflammation markers like IL-6 and C-reactive protein but did not lower patients' risk of heart attacks or strokes. Additionally, more participants on the treatment experienced serious infections compared to those receiving a placebo. The failure is expected to impact future revenue potential rather than current 2026 financial projections. Investors had hoped ziltivekimab would diversify Novo Nordisk's portfolio beyond diabetes and weight-loss drugs like Ozempic and Wegovy, which have driven recent growth.
Tickers: $NVO
Topics: cardiovascular drug development clinical trial failure ziltivekimab